In this report we describe our experience with two patients in order to evaluate the clinical potential of a reduced intensity stem cell transplantation in a more difficult clinical setting, i.e. second transplant with a one- or two-antigen mismatched related donor for relapsed and refractory leukemia. Three benefits were hoped for: 1) reduced regimen-related toxicity, 2) potent engraftment facilitation, and 3) an intense anti-leukemia effect.
|出版ステータス||Published - 2001 8 7|
ASJC Scopus subject areas